Kilitch Drugs
138.95
-13.85(-9.06%)
Market Cap₹485.79 Cr
PE Ratio21.48
IndustryHealthcare
Company Performance:
1D-9.06%
1M-56.53%
6M-59.79%
1Y-59.96%
5Y+74.32%
View Company Insightsright
More news about Kilitch Drugs
25Aug 25
Kilitch Drugs Reschedules Rights Issue Credit and Listing Dates
Kilitch Drugs (India) Limited has announced changes to its rights issue timeline. The credit of Rights Equity Shares is rescheduled from August 25, 2025, to August 26, 2025, and the listing of Rights Equity Shares is moved from August 26, 2025, to August 28, 2025. The company is offering 13,98,463 equity shares at Rs. 357 per share, totaling Rs. 4,992.51 lakhs. The rights issue ratio is 2:23. Post-rights issue, the company's paid-up equity share capital will increase from 1,60,82,319 to 1,74,80,782 shares.
 no imag found
22Aug 25
Kilitch Drugs Postpones Rights Issue Allotment Process by Three Days
Kilitch Drugs (India) Limited has postponed the finalization of its Rights Issue allotment from August 22 to August 25, 2025. The Rights Issue involves offering 13,98,463 equity shares at Rs. 357 per share, totaling approximately Rs. 49.93 crores. The delay, decided in consultation with NSE and the Registrar, is due to the ongoing finalization and allotment process requiring additional time. The Rights Issue, approved on July 12, 2025, offers 2 rights equity shares for every 23 shares held, with July 15, 2025, as the record date.
 no imag found
13Aug 25
Kilitch Drugs Reports Robust Q1 Results with 131% Surge in Net Profit
Kilitch Drugs (India) Limited announced impressive Q1 FY2026 financial results. Consolidated net sales increased by 28.96% to ₹4,313.98 lakhs, while net profit surged by 130.94% to ₹226.25 lakhs. EBITDA grew by 37.55% to ₹582.20 lakhs, with the EBITDA margin improving to 13.50%. Standalone performance also showed growth, with net sales up 2.10% and net profit after tax increasing by 18.26%. The company's board has approved a rights issue of 13,968,463 equity shares at ₹357 per share, totaling ₹4,992.51 lakhs.
 no imag found
09Jul 25
Kilitch Drugs Announces Rights Issue at ₹357 Per Share
Kilitch Drugs' Board of Directors has approved a rights issue priced at ₹357.00 per share. This corporate action allows existing shareholders to purchase additional shares, potentially at a discount, to maintain their ownership percentage. The company aims to strengthen its capital base, though specific plans for the raised funds are not disclosed. Shareholders should await further details on the issue ratio, record date, and timeline.
 no imag found
20May 25
Kilitch Drugs Reports Impressive Q4 Results with Soaring Profits and Revenue
Kilitch Drugs announced impressive Q4 financial results, with net profit more than doubling to ₹104.40 crore from ₹46.80 crore year-over-year. The company's revenue surged to ₹563.00 crore, up from ₹391.00 crore in the same quarter last year. Sequentially, net profit also showed significant improvement, increasing from ₹56.50 crore in the previous quarter.
 no imag found
Kilitch Drugs
138.95
-13.85
(-9.06%)
1 Year Returns:-59.96%
Industry Peers
Sun Pharmaceutical
1,793.60
(-0.10%)
Divis Laboratories
5,997.50
(-0.28%)
Torrent Pharmaceuticals
4,265.60
(-0.74%)
Dr Reddys Laboratories
1,281.70
(-1.46%)
Lupin
2,334.80
(-0.55%)
Cipla
1,242.30
(-0.17%)
Zydus Life Science
896.70
(-0.77%)
Mankind Pharma
2,038.80
(+0.73%)
Aurobindo Pharma
1,314.20
(+0.49%)
Alkem Laboratories
5,344.50
(-1.67%)